Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin alpha 1 in sepsis (TESTS)
NCT02867267Phase 3Completed
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2016
- Primary completion
- Jan 2021
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis comparing Thymosin alpha 1 Arm with Placebo Arm (2 arms). Primary endpoint: 28-day all-cause mortality. Started Sep 2016; status: completed.
02
Drugs
thymosin alpha 1
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT02867267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867267.